Xponance Inc. Buys 628 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Xponance Inc. raised its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.8% in the fourth quarter, Holdings Channel reports. The fund owned 13,609 shares of the biopharmaceutical company’s stock after acquiring an additional 628 shares during the period. Xponance Inc.’s holdings in Intra-Cellular Therapies were worth $1,137,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. M&T Bank Corp increased its position in shares of Intra-Cellular Therapies by 2.2% during the 4th quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock worth $526,000 after purchasing an additional 138 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Intra-Cellular Therapies by 1.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 141 shares in the last quarter. CIBC Asset Management Inc raised its stake in shares of Intra-Cellular Therapies by 5.3% in the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 150 shares during the last quarter. Pallas Capital Advisors LLC boosted its holdings in shares of Intra-Cellular Therapies by 6.4% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 192 shares in the last quarter. Finally, Arizona State Retirement System grew its position in Intra-Cellular Therapies by 0.8% during the 4th quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company’s stock worth $2,302,000 after acquiring an additional 206 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Piper Sandler reiterated a “neutral” rating and set a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Up 0.0 %

NASDAQ:ITCI opened at $131.65 on Monday. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.67. The stock’s fifty day simple moving average is $128.61 and its 200-day simple moving average is $97.76. The firm has a market capitalization of $14.00 billion, a P/E ratio of -151.32 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.